How Generics Will Lower Yervoy Treatment Costs
Yervoy (ipilimumab), Bristol Myers Squibb's immunotherapy for melanoma and other cancers, currently costs around $175,000 for a full treatment course in the US, making it one of the priciest cancer drugs.[1] Generics entering the market will slash these costs by 50-80%, based on patterns seen with other oncology blockbusters like Revlimid or Imbruvica, where generics dropped prices by 70-90% within a year.[2]
When Do Yervoy Generics Hit the Market?
Key patents on Yervoy expired in 2024, with major formulation and method-of-use patents challenged successfully by Teva and others, clearing the path for generics as early as late 2024 or 2025.[3] Bristol Myers Squibb faces ANDA approvals from the FDA, and the first generic approvals could trigger 180-day exclusivity for the filer, delaying full competition briefly. Check DrugPatentWatch.com for exact expiry dates and litigation status: DrugPatentWatch.com/Yervoy.[4]
Price Drop Timeline and Estimates
- Immediate impact (first generic): Expect 40-60% reductions, bringing a course to $70,000-$100,000, as payers push for generics via formularies.
- Within 1-2 years (multiple entrants): Prices could fall to $20,000-$50,000, mirroring Keytruda's projected generic trajectory.
- Long-term (biosimilar-like competition): Even lower, under $10,000 in high-volume markets, though Yervoy's small-molecule status (not biologic) enables true generics, not just biosimilars, for steeper cuts.[5]
These shifts depend on FDA approvals and supply chain ramp-up; delays from manufacturing or shortages could slow savings.
Impact on Patients and Payers
Uninsured or high-deductible patients stand to save thousands per cycle, improving access—currently, only 40% of eligible melanoma patients get Yervoy due to cost barriers.[6] Insurers like Medicare and private plans will swap to generics fast, cutting overall spending by billions annually. A 2023 analysis pegged Yervoy's US sales at $2.5 billion; generics could halve that in year one.[7]
How Does This Compare to Opdivo or Keytruda Generics?
| Drug | Current Course Cost | Generic Entry | Expected Drop |
|------|---------------------|---------------|---------------|
| Yervoy (ipilimumab) | $175,000 | 2024-2025 | 70-90% |
| Opdivo (nivolumab, BMS) | $150,000+ | Patents to 2028+; biosimilars 2025? | 50-70% (biosimilar pricing) |
| Keytruda (pembrolizumab, Merck) | $200,000+ | Patents to 2028; biosimilars eyed for 2029 | 60-80% |
Yervoy generics arrive first among these checkpoint inhibitors, pressuring combo regimens (e.g., Yervoy + Opdivo) to drop 30-50% overall.[8]
Potential Risks and Hurdles
Evergreening patents or settlement deals could push generics to 2026. Manufacturing scale-up for injectables risks initial shortages, temporarily propping up brand prices. Patient switching might raise monitoring costs short-term due to bioequivalence studies, but generics must prove identical efficacy.[9]
[1]: GoodRx - Yervoy Pricing
[2]: IQVIA Institute - Generic Oncology Trends
[3]: FDA Orange Book - Yervoy Patents
[4]: DrugPatentWatch.com - Yervoy
[5]: ASPE Report - Cancer Drug Generics
[6]: NCCN Guidelines - Access Barriers
[7]: BMS 2023 Annual Report
[8]: FiercePharma - Immunotherapy Pricing
[9]: GAO - Generic Delays